Halozyme Therapeutics（NASDAQ:HALO）公佈了季度財報，公司調整後每股收益爲$1.26，高於分析師普遍預期的$1.16，上漲幅度達8.62%。與去年同期的每股收益$0.82相比，這一數字增長了53.66%。公司報告的本季度銷售額爲$2.98億，超出分析師預期的$2.88億，超出幅度爲3.39%。較去年同期$2.30億的銷售額相比增加了29.54%。

以上內容來自Benzinga Earnings專欄，原文如下：

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.16 by 8.62 percent. This is a 53.66 percent increase over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $298.00 million which beat the analyst consensus estimate of $288.24 million by 3.39 percent. This is a 29.54 percent increase over sales of $230.04 million the same period last year.